Clinical Trials Sponsored by Fundación BBVA

Total 2327 results

University of Deusto
Fundación BBVA

Completed

Wise Interventions in the Digital Society

Risk Behavior | Cyberbullying | Grooming

Spain
Universidad de Granada
Fundación BBVA; Universidad Loyola Andalucia

Not yet recruiting

Lifestyle Intervention for Obstructive Sleep Apnea in Women (INTERAPNEA-W)

Obstructive Sleep Apnea
Tibotec BVBA

Completed

TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)

HIV Infections

South Africa
Tibotec BVBA

Completed

A Study of TMC207 in Patients With Moderately Impaired Hepatic Function

Moderate Hepatic Impairment
Tibotec BVBA

Completed

TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral Doses of TMC207 in Subjects With Sputum-Smear Positive Tuberculosis

Tuberculosis
Tibotec BVBA

Completed

VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state.

Hepatitis C | HIV | Telaprevir
Tibotec BVBA

Completed

An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants

Chronic Hepatitis C

France, Spain, Belgium, Germany, Austria, Netherlands
Tibotec BVBA

Completed

An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection

Hepatitis C
Tibotec BVBA

Completed

A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection

Hepatitis C, Chronic

France, United Kingdom, Sweden
Tibotec BVBA

Completed

A Study to Determine the Relative Oral Bioavailability of Single Dose Administration of TMC207, Under Fed and Fasted Conditions in Healthy Participants

Healthy
Tibotec BVBA

Completed

TMC207TBC1003 - A Study in Healthy Volunteers Investigating the Effect of Single-dose TMC207 on the QT/QTc Interval Under Fed Conditions

Healthy Volunteer
Tibotec BVBA

Completed

TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer

HIV | Tuberculosis
Tibotec BVBA

Completed

VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy Volunteer

Hepatitis C | HIV | HCV | AIDS
Rousselot BVBA

Not yet recruiting

An Open Label, Dose-escalation Study, Assessing the Safety and Tolerability of a Collagen Peptide

Tolerance

United States
Tibotec BVBA

Terminated

TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin

Hepatitis C Virus

Poland, Netherlands
Tibotec BVBA

Completed

VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram

Hepatitis C
Tibotec BVBA

Completed

VX-950-TiDP24-C132: A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Telaprevir.

Kidney Diseases | Hepatitis C
MSD Belgium BVBA

Completed

BEPACT- Lung: Impact of Patient Characteristics on Pneumo-oncologists Non Small Cell Lung Cancer (NSCLC) Systemic Treatment Decision in Belgium (BEPACT- Lung)

Stage IV Non-small Cell Lung Cancer

Belgium
Fundación GECP

Recruiting

Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy (MERIT-lung)

Non-small Cell Lung Cancer Stage III | KRAS P.G12C

Spain
Fundación EPIC

Recruiting

Essential Pro PMCF Study ( rEPIC04E ) (rEPIC04E)

Ischemic Heart Disease | Coronary Artery Disease (CAD)

Spain
Fundación GECP

Recruiting

Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases (NIVIPI-Brain)

Lung Cancer | Non Small Cell Lung Cancer | Brain Metastases, Adult

Spain
Fundación GECP

Recruiting

Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma (BIMES)

Mesothelioma; Lung

Spain
Fundación EPIC

Recruiting

ANGiographic Evaluation of Left Main Coronary Artery INtErvention (ANGELINE)

Coronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery Stenosis

Spain
Fundación GECP

Recruiting

Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients

Non Small Cell Lung Cancer | EGFR Gene Mutation

Spain
Fundación EPIC

Active, not recruiting

Concordance Between FFR and iFR for the Assessment of Intermediate Lesions in the Left Main Coronary Artery. A Prospective Validation of a Default Value for iFR (iLITRO)

Coronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, Coronary

Spain
Fundación EPIC

Completed

NAVISCORE PMCF Study ( rEPIC04F ) (rEPIC04F)

Coronary Artery Disease | Ischemic Heart Disease

Spain
Fundación GECP

Active, not recruiting

New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy (NADIM-ADJUVANT)

Non-Small Cell Lung Cancer | Adjuvant Chemotherapy

Spain
Fundación EPIC

Completed

Laser-excimer Versus High-pressure Dilation to Treat Under-expansion of the Stent (LASER EXPAND)

Cardiovascular Diseases | Arterial Disease

Spain
Fundación GECP

Active, not recruiting

Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients (CUBIK)

NSCLC | Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB

Spain
Fundación EPIC

Completed

Xperience Pro PMCF Study (rEPIC04A)

Ischemic Heart Disease | Coronary Artery Disease (CAD)

Spain
Fundación Campbell

Completed

Medial Tab Flap for Soft Tissue Defects of the Leg

Leg Coverage Defects

Colombia
Fundación EPIC

Active, not recruiting

Evaluation of Ambulatory Monitoring of Patients After High-risk Acute Coronary Syndrome Using Two Different Systems: Biomonitor-2 and Kardia Mobile (Monitor- ACS)

Heart Diseases | Atrial Fibrillation | Arrhythmias, Cardiac | Syncope | Tachycardia

Spain
Fundación GECP

Completed

Anti-SARS-COV2 Vaccination Study in Lung Cancer Patients (VAC-CaP)

Covid19 | Lung Cancer

Spain
Fundación EPIC

Active, not recruiting

Registry of Coronary Lithotripsy in Spain. (REPLICA)

Cardiovascular Diseases | Vascular Diseases | Coronary Artery Disease | Arteriosclerosis | Arterial Occlusive Diseases

Spain
Fundación GECP

Completed

Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive (OSIREX)

Non Small Cell Lung Cancer

Spain
Fundación EPIC

Active, not recruiting

PRospective Evaluation Complementing Investigation With Acurate Neo Device (PRECISA)

Aortic Stenosis

Spain
Fundación Senefro

Completed

Anemia Management in Chronic Kidney Disease Not on Dialysis Patients After the European Renal Best Practice (ERBP) Working Group Recommendations (ACERCA)

ANEMIA

Spain
Fundación EPIC

Recruiting

Plan to Evaluate Early Endothelialization of a Polymer Free Sirolimus-eluting Coronary Stent System (VIVO ISARTM) Compared With Everolimus-eluting Durable Polymer Stent (XIENCE SkypointTM) in Patients Undergoing Percutaneous Coronary Intervention.

Coronary Artery Disease

Spain
Fundación EPIC

Recruiting

Comparison of Allegra vs Sapien Transcatheter Aortic Valves in Valve-In-Valve Indication

Aortic Valve Stenosis | Structural Valve Deterioration

Spain
Fundación GECP

Recruiting

DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors (DUMAS)

NSCLC | Pancoast Tumor

Spain
Fundación GECP

Recruiting

Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer (PEERS)

Small Cell Lung Cancer Extensive Stage

Spain
Fundación GECP

Recruiting

Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment (REAL-NADIM)

Neoadjuvant Treatment | Non Small Cell Lung Cancer Stage III

Spain
Fundación EPIC

Recruiting

ANGIOLITE PMCF Study ( rEPIC04F ) (rEPIC04F)

Ischemic Heart Disease | Coronary Artery Disease (CAD)

Spain
Fundación EPIC

Recruiting

CAPTURER PMCF Study ( rEPIC04D ) (rEPIC04D)

Ischemic Heart Disease | Coronary Artery Disease (CAD)

Spain
Fundación GECP

Recruiting

Pathological Response After Neoadjuvant Treatment on NSCLC (PLANET)

Stage IIIA Non-small Cell Lung Cancer

Spain
Fundación IVI

Recruiting

Umbilical Cord Plasma for Treating Endometrial Pathologies (Thin Endometrium / Asherman's Syndrome/ Endometria Atrophy) (hSCU-PRP)

Asherman Syndrome | Endometrial Atrophy

Spain
Fundación IVI

Recruiting

Comparison of ICSI Outcomes in Cycles Using Testicular and Ejaculate Sperm From Couples With High SDF

DNA Damage | IVF | Oligospermia | ICSI | Embryo

Spain
Fundación GECP

Recruiting

Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) (APOLO)

Lung Diseases | Carcinoma, Non-Small-Cell Lung | Respiratory Tract Neoplasms | Thoracic Neoplasms | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Carcinoma Bronchiogenic Stage III

Spain
Fundación EPIC

Recruiting

VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA)

Coronary Artery Disease | Acute Coronary Syndrome | Percutaneous Coronary Intervention | Acute Myocardial Infarction

Spain
Fundación EPIC

Recruiting

Evaluation of the Safety and Efficacy of Titanium-nitric Oxide-coated Stent (Optimax®) in Patients With Lesions With a Low Risk of Restenosis (Diameter ≥ 3.0 mm and Length ≤ 20 mm) (RETO 320)

Coronary Artery Disease

Spain

3

Subscribe